Page 27 - ASPIRE JANUARY 2023 Volume 8 / Issue 1

ENDOMETRIUM & IMPLANTATION SIG
Rong Li (China)
AMH in gynaecological
endocrinology, oncology,
assisted reproduction,
and other related fields
By Drs Rong Li and Keiji Kuroda
We recently held another successful ASPIRE-CPAM Masterclass Webinar Series that focused on AMH and reproductive endocrine diseases.
In the past few decades, we have carried out a lot of research on AMH in gynaecological endocrinology, oncology, assisted reproduction and other related fields.
The detection of AMH is basically independent of the menstrual cycle, and it can reflect the ovarian reserve function of women earlier and more accurately. It is of great significance for the health management of perimenopausal women, the diagnosis of ovarian granulosa cell tumour, and abnormal sexual differentiation.
Keiji Kuroda (Japan)
In recent years, many studies have taken it as one of the new criteria for the diagnosis of polycystic egg nest syndrome, which is helpful to develop personalised stimulation programs in the process of assisted reproduction, to reduce complications, and to improve pregnancy rates.
In view of these advantages, AMH is widely used in clinical practice. The masterclass webinar series was co-chaired by Chairman Li Rong and Somjate Manipalviratn from the Jetanin Institute of Assisted Reproduction, Bangkok, Thailand.
Professor Yang Dongzi from Sun Yat sen Memorial Hospital of Sun Yat sen University, and Director Duru Shah from Gynaecworld Women’s Health and Reproduction Centre in India were invited to conduct in-depth discussion on the clinical application of AMH and the related research on polycystic ovary syndrome.
We will continue to share topics related to cost- effectiveness considerations of ovarian stimulation treatment and we welcome your support.
25